Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3258-3267

  Lu, Yingjuan ^a   Xu, Le Cun ^a   Parker, Nikki ^a   Westrick, Elaine ^a   Reddy, Joseph A ^a   Vetzel, Marilynn ^a   Low, Philip S ^b   Leamon, Christopher P ^a  

^a Endocyte Inc   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOLATE HAPTEN CONJUGATE; FOLATE RECEPTOR; HAPTEN ANTIBODY; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TREATMENT DURATION;

ANIMALS; CYTOKINES; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FOLIC ACID; HAPTENS; IMMUNOCONJUGATES; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION; TRITIUM;

EID: 33846210997     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0439     Document Type: Article

References (21)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
2. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55:3369-73.
3. Wang G, Chopra RK, Royal RE, et al. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Mad 1998;4:168-72.
4. Kim DK, Lee TV, Castilleja A, et al. Folate binding protein peptide 191 - 199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 1999;19:2907-16.
5. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 2002;25:189-201.
6. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002;51:153-62.
7. Lu Y, Saga E, Leamon CP, Low PS. Folate-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004; 56:1161-76.
8. Lu Y, Saga E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J of Cancer 2005;116:710-9.
9. Kennedy MD, Jallad KN, Lu J, Low PS, Ben-Amotz D. Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharm Res 2003;20:714-9.
10. Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 2003;8:636-41.
11. Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000;37 Suppl 3:41-4.
12. Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701.
13. Holmberg LA, Oparin DV, Gooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope(R)). Clin Breast Cancer 2003;3 Suppl 4:S144-51.
14. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-20.
15. Kamen BA, Caston JD. Purification of folate binding factor in normal umbilical cord serum. Proc Natl Acad Sci U S A 1975;72:4261-4.
16. Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 2000; 19:530-7.
17. Ragulpathi G, Coltart DM, Williams LJ, et al. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc Natl Acad Sci U S A 2002;99:13699-704.
18. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Mad 2004;45:857-66.
19. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205-17.
20. Wang P, Nakamura K, Mimura Y, et al. Immune response to different doses of a hapten of fluorescein isothiocyanate analyzed by two-dimensional affinity electrophoresis. Electrophoresis 1996;17:1273-9.
21. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 1995;92:1254-6.